Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant

Abstract The huge worldwide demand for vaccines targeting SARS-CoV-2 has necessitated the continued development of novel improved formulations capable of reducing the burden of the COVID-19 pandemic. Herein, we evaluated novel protein subunit vaccine formulations containing a resistin-trimerized spi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bassel Akache, Tyler M. Renner, Anh Tran, Lise Deschatelets, Renu Dudani, Blair A. Harrison, Diana Duque, Julie Haukenfrers, Martin A. Rossotti, Francis Gaudreault, Usha D. Hemraz, Edmond Lam, Sophie Régnier, Wangxue Chen, Christian Gervais, Matthew Stuible, Lakshmi Krishnan, Yves Durocher, Michael J. McCluskie
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/9618e29b6e8e4f74b75065bea762626c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant

Ejemplares similares